Kerri Neel
Nurse Practitioner · York, MENPI 1023074424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 34.0% of the total. 2025 is the largest year on record at $2,016, 2.1 times the $971 reported in 2022. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$405
- Lilly USA, LLC$353
- Teva Pharmaceuticals USA, Inc.$316
- Lundbeck LLC$282
- GSK$208
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,96498%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,721 |
| Pfizer | 24 | $405 |
| Lilly USA, LLC | 14 | $353 |
| Teva Pharmaceuticals USA, Inc. | 23 | $316 |
| Lundbeck LLC | 16 | $282 |
| GSK | 7 | $208 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $177 |
| Bayer | 8 | $174 |
| Ironshore Pharmaceuticals Inc. | 3 | $172 |
| Novo Nordisk | 9 | $163 |
| Astellas Pharma US Inc | 2 | $112 |
| Exact Sciences | 6 | $111 |
| Boehringer Ingelheim | 6 | $100 |
| Daiichi Sankyo Inc. | 4 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $80 |
| Collegium Pharmaceutical, Inc. | 3 | $69 |
| Acadia Pharmaceuticals Inc | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Biogen | 2 | $47 |
| Tonix Medicines, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Insightec,inc | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,054 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 37 | $38,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $29,714 |
| VyvanseLisdexamfetamine Dimesylate | 39 | $24,248 |
| EliquisApixaban | 19 | $22,888 |
| XareltoRivaroxaban | 18 | $20,335 |
| OzempicSemaglutide | 18 | $18,130 |
| Lisdexamfetamine Dimesylate | 30 | $6,580 |
| Epinephrine | 15 | $2,427 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,860 |
| Bupropion XlBupropion Hcl | 45 | $1,835 |
| SynthroidLevothyroxine Sodium | 18 | $1,800 |
| Arnuity ElliptaFluticasone Furoate | 11 | $1,769 |
| Atorvastatin Calcium | 179 | $1,526 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,429 |
| Omeprazole | 83 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $353 | $38,85737 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $208 | $31,48339 claims |
| PfizerEliquis, Paxlovid | $405 | $24,31730 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $177 | $24,24839 claims |
| Novo NordiskOzempic | $163 | $18,13018 claims |
| AbbVieSynthroid | $1,721 | $1,80018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.
Other nurse practitioner in York
- Mallory EvansYork$5K
- Ashley MaceYork$2K
- Julie WarkYork$693
- Vera IvanovaYork$470
- Amanda MagnoliWestbrook$113K
- Gisele CastonguayLewiston$26K
- Rachel Koransky-MatsonBangor$16K
- Denise ViekmanPortland$15K
- Karrie SweetPortland$5K
- Noelle CooperSouth Portland$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.